🇺🇸 FDA
Patent

US 10822608

Oligonucleotide analogues targeting human LMNA

granted A61PA61P43/00

Quick answer

US patent 10822608 (Oligonucleotide analogues targeting human LMNA) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61P, A61P43/00